Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2024-10-29 Regulatory Filings
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is titled 'Selskabsmeddelelse nr. 20' (Company Announcement no. 20) and is dated October 29, 2024. It announces a specific operational milestone: the enrollment of the first patient in a US clinical study for their product ProNephro AKI (NGAL)™. It also explicitly states that the content does not affect the 2024 financial guidance and includes forward-looking statements. This structure—a specific, time-sensitive operational update released via a formal announcement mechanism (often associated with stock exchange requirements)—is characteristic of a general regulatory filing or announcement that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement that doesn't fit the more specific categories (like DIV, DIRS, MANG, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length (8047 chars) is substantial enough that it is the report itself, not just a link announcement (RPA).
2024-10-29 Danish
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a press release dated October 29, 2024, titled "First Patient In - BioPorto Initiates Patient Enrollment for US Study...". It announces a specific operational milestone (starting patient enrollment for a clinical study) and references previous financial reporting periods ("Interim Report for the second quarter of 2024"). It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a formal Earnings Release (ER). It is a specific corporate update regarding clinical progress and regulatory pathway. Since it is a specific announcement that doesn't fit the other specialized categories (like DIRS, DIV, MANG, etc.), and it is not merely announcing the publication of a major report (which would suggest RPA), it falls best under the general category for regulatory/corporate announcements that are not financial results or governance changes. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for specific, non-financial, operational news releases that are disseminated broadly, especially when the content is highly specific to clinical trials and FDA submissions.
2024-10-29 English
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse nr. 20) from BioPorto regarding the enrollment of the first patient in a clinical study for their ProNephro AKI (NGAL) product. It is a regulatory announcement detailing operational progress and clinical trial milestones. Since it does not fit into specific categories like financial reports, board changes, or dividend notices, and serves as a general regulatory update for shareholders, it is classified as a Regulatory Filing (RNS).
2024-10-29 Danish
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital
Regulatory Filings Classification · 98% confidence The document is a corporate announcement regarding the initiation of patient enrollment for a clinical study of the company's ProNephro AKI (NGAL) product. It details operational progress, clinical trial milestones, and management commentary. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple report publication announcement. As it is a general regulatory announcement regarding company operations and clinical progress, it falls under the RNS (Regulatory Filings) category.
2024-10-29 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a press release dated October 28, 2024, announcing a 'global distribution partnership' between BioPorto and Beckman Coulter for NGAL tests. This type of announcement, detailing a strategic business agreement, partnership, or corporate development that is not a mandatory financial filing (like 10-K, ER, or IR), typically falls under general regulatory announcements or news releases. Since it is not a specific financial report, management change, dividend notice, or transaction report, the most appropriate category is the general regulatory announcement/news category, which is RNS (Regulatory Filings). It is too specific for a generic 'LTR' (Legal Proceedings) or 'CAP' (Financing Update), and it is clearly not a formal financial report (10-K, IR) or a transcript (CT).
2024-10-28 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is titled "Selskabsmeddelelse nr. 19" (Company Announcement No. 19) and details a significant business event: a global distribution partnership between BioPorto and Beckman Coulter regarding NGAL tests for acute kidney injury. This type of announcement, which details strategic business developments, partnerships, or material corporate news that is not a standard periodic financial report (like 10-K or IR) or a specific regulatory filing (like DIRS or DIV), typically falls under general regulatory announcements or news releases. Since it is a formal announcement of a material event, and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate general category for a significant, non-standard corporate disclosure is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered elsewhere. The length (5763 chars) is substantial enough that it is the announcement itself, not just a notice of publication (RPA).
2024-10-28 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.